Sanofi and Regeneron Pharmaceuticals, Inc.'s Libtayo (cemiplimab) looks likely to extend its recent run of regulatory approvals as an oncology treatment after the PD-1 inhibitor became the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer.
Positive results from a Phase III trial evaluating Libtayo as a monotherapy for patients whose cervical cancer is recurrent or metastatic showed the product cut the risk of death by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?